[Federal Register Volume 75, Number 96 (Wednesday, May 19, 2010)]
[Notices]
[Page 28028]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-12006]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Cancer Institute Clinical Trials and Translational Research
Advisory Committee.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: National Cancer Institute Clinical Trials and
Translational Research Advisory Committee.
Date: July 14, 2010.
Time: 8 a.m. to 4 p.m.
Agenda: Update on the progress of the implementation of the
Clinical Trials Working Group and the Translational Research Working
Group reports.
Place: National Institutes of Health, Building 31, 6th Floor, C-
Wing, Room 10, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Sheila A. Prindiville, MD, MPH, Director,
Coordinating Center for Clinical Trials, Office of the Director,
National Cancer Institute, National Institutes of Health, 6120
Executive Blvd., 3rd Floor Suite, Bethesda, MD 20892, 301-451-5048,
[email protected].
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: May 17, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-12006 Filed 5-18-10; 8:45 am]
BILLING CODE 4140-01-P